Clinical Trial Update: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase II study of Olokizumab for Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Crohn's Disease | Phase 2 | Status: WITHDRAWN